

Synthesis and Pharmacological Evaluation of 6-Piperidino- and 6-Piperazinoalkyl-2(3*H*)-benzothiazolones as Mixed $\sigma/5\text{-HT}_{1A}$ Ligands

Ange Mouithys-Mickalad,^{a,*} Jacques H. Poupaert,^b Santi Spampinato^c and Daniel Lesieur^a

^a*Institut de Chimie Pharmaceutique Albert Lespagnol, Université de Lille 2, 3, rue du Professeur Laguesse, F-59006 Lille, France*

^b*Ecole de Pharmacie, Université Catholique de Louvain, Avenue E. Mounier 73, B-1200 Bruxelles, Belgium*

^c*Dipartimento di Farmacologia, Facoltà di Farmacia, Università degli Studi di Bologna, 48 via Irnerio, I-40126 Bologna, Italy*

Received 2 November 2001; revised 1 February 2002; accepted 18 February 2002

Abstract—In an effort to produce new pharmacological probes with mixed $\sigma/5\text{-HT}_{1A}$ affinity, we have synthesized a series of 12 original 6-piperidino- or piperazino-alkyl-2(3*H*)-benzothiazolones and their receptor binding profile (σ , 5-HT_{1A} , 5-HT_{2A} , 5-HT_3 , D_2 , H_1 , and M_1) was determined. The best mixed $\sigma/5\text{-HT}_{1A}$ affinity profile was found within the piperidine series with 4-benzyl substitution associated to linker methylene chain $n=2$ (K_i 5 and 4 nM, respectively). Moreover, a highly selective σ_2 ligand was obtained with a 3,4-dichlorobenzyl substitution associated to $n=4$ (K_i 2 nM, selectivity ratio $\sigma_1/\sigma_2=70$). © 2002 Elsevier Science Ltd. All rights reserved.

The serotonin 5-HT_{1A} receptor has been implicated in a lot of physio-pathogenic processes including the regulation of cognition, psychosis, feeding/satiety, temperature regulation, anxiety, depression, sleep, pain perception, and sexual activity.¹ The development of non-benzodiazepine anxiolytics such as buspirone (**1**) (Fig. 1), a partial agonist at 5-HT_{1A} receptors, has substantiated the correlation between serotonin and anxiety.² In addition, there has been a recent report that flesinoxan (**2**), a 5-HT_{1A} full agonist, is effective in generalized anxiety disorder in humans.³ On the contrary, the 5-HT_{1A} receptor antagonists, (+)-WAY-100135 (**3**) and WAY-100635 (**4**), show limited anxiolytic activity.⁴ In contrast, **3** and **4** have shown robust activity in a number of preclinical models of cognitive impairment associated with Alzheimer's disease.⁵ Harder et al.⁶ reported that **4** alleviates impairments caused by dizocilpine (MK-801), a non-competitive NMDA antagonist, in monkeys. Similarly, Boast et al.⁷ found that **4** significantly reduced the cognitive impairment caused by MK-801, in a delayed non-match to sample radial arm maze task in rats.

Furthermore, Carli et al.⁸ showed that post-training administration of WAY-100635 was able to reverse a learning deficit induced in rats by administration of




Figure 1. Structure of some 5-HT_{1A} ligands.

*Corresponding author at: CORD, University of Liège, B6a, Sart Tilman, B-4000 Liège, Belgium. Fax: +32-4-366-2866; e-mail: amouithys@ulg.ac.be




Figure 2. Some examples of sigma 1 and 2 ligands.

scopolamine, a cholinergic antagonist, in an auto-shaping learning task.

It is noteworthy that **1–4** all have in common a *N*-aryl-piperazine moiety in their structure (Fig. 1).

On the other hand, sigma receptors are involved in a number of physio-pathological functions such as modulation and biosynthesis of several neurotransmitters, motor control, and cell growth and proliferation.⁹ The lack of endogenous ligands (progesterone, neuropeptide Y, and substance P fragments remain debatable candidates)^{10–13} and the existence of at least two sigma receptor subtypes, termed σ_1 and σ_2 ,¹⁴ have hampered so far major clinical applications. Recently, a mammalian protein which binds σ_1 ligands has been cloned and showed no homology to known mammalian proteins.¹⁵

The sustained interest for σ ligands stems from the possibility of developing clinical agents for the treatment of psychiatric and motor disorders,¹⁶ tumor diagnosis,¹⁷ cocaine,¹⁸ neuroprotection,¹⁹ and other neurological diseases. Several classes of structurally unrelated compounds interact with these receptors and unfortunately σ ligands in general display low selectivity.^{20,21} Among potent and selective σ_1 ligands are the *cis*-(+)-*N*-substituted normetazocine derivatives, that is (+)-pentazocine, (+)-*N*-allyl-normetazocine (SKF 10,047) (Fig. 2), and (+)-*N*-benzyl-*N*-normetazocine.²² The list of σ_2 selective ligands is more limited (Fig. 2). Examples of σ_2 selective ligands are (+)-1*R*,5*R*-(*E*)-8-benzylidene-5-(3-hydroxyphenyl)-2-methylmorphane-7-one and its 3,4-dichloro derivative (CB64D and CB184, respectively).²³ A decade ago attempts were made to separate sigma binding from 5-HT_{1A} binding in order to achieve greater selectivity; one of the first papers to address this issue in a series of arylalkylamines was published by Glennon et al.²⁴





Figure 3. General structure of the mixed sigma/5-HT_{1A} ligands (*n*=number of methylenes, R=H or CH₃, X=N or CH, Y=phenyl, benzyl, 2,4- or 3,4-dichlorobenzyl).

Table 1. Preparation of 6-piperidino and 6-piperazinoalkyl-2(3*H*)-benzothiazolones according to Scheme 1

Compd	n	R	X	Y	Yield (%)
6	2	H	CH	Phenyl	60
7	4	H	CH	Phenyl	43
8	2	H	CH	Benzyl	56
9	4	H	CH	Benzyl	50
10	2	H	N	Benzyl	45
11	4	H	N	Benzyl	55
12	2	H	N	2,4-Cl ₂ C ₆ H ₃ CH ₂ –	60
13	4	H	N	2,4-Cl ₂ C ₆ H ₃ CH ₂ –	42
14	2	H	N	3,4-Cl ₂ C ₆ H ₃ CH ₂ –	56
15	4	H	N	3,4-Cl ₂ C ₆ H ₃ CH ₂ –	45
16	2	CH ₃	N	H	60
17	4	CH ₃	N	H	40

Several recent publications support the hypothesis that sigma and 5-HT_{1A} ligands may serve as atypical anti-psychotic agents with minimal extra-pyramidal side effects.^{25–27} Consequently, in an effort to produce new pharmacological probes with mixed σ /5-HT_{1A} affinity, we have synthesized a series of 12 original 6-piperidino- or piperazino-alkyl-2(3*H*)-benzothiazolones (Fig. 3) and their receptor binding profile (σ , 5-HT_{1A}, 5-HT_{2A}, 5-HT₃, D₂, H₁, and M₁) was determined. The design of these ligands was based on the following arguments: (i) CoMFA investigations showed that almost all sigma ligands are characterized by a central basic nitrogen flanked by two aromatic hydrophobic groups;²⁰ (ii) it is well established that the *N*-phenylpiperazine moiety are good 5-HT_{1A} and σ pharmacophores;²⁸ (iii) 2(3*H*)-benzothiazolones have been successfully used as template both in the 5-HT_{1A} and sigma axis.^{29,30} The nature of substituents and the reaction yield of these ligands are reported in the Table 1 and their corresponding binding affinities are listed in the Table 2. Their synthetic approach is shown in the Scheme 1.

Most of these compounds exhibited rather high affinity (in the nanomolar range) at sigma and/or 5-HT_{1A} receptors. Within the piperidine series, binding studies showed that for sigma affinity 4-phenyl substitution was



Scheme 1. Synthesis pathway of 6-piperidino or 6-piperazinoalkyl-2(3*H*)-benzothiazolones (**6–17**). Reagents and conditions: (a) BrCH₂COCl, AlCl₃–DMF; (b) Et₃SiH, TFA; (c) Cl(CH₂)₃COCl, PPA; (d) HBr (gas), acetone, 20 °C; (e) secondary cyclic amine, Et₃N, acetone reflux, for 24 h; (f) heterocyclic amine, K₂CO₃, DMF, for 5 h.

Table 2. Binding affinities of 6-piperidino and 6-piperazinoalkyl-2(3*H*)-benzothiazolones. Binding measurements were done in triplicate and sigma binding refers to displacement of [³H]-DTG

Compd	<i>K_i</i> (nM)							
	Sigma	5-HT _{1A}	5-HT _{2A}	5-HT ₃	D ₂	H ₁	M ₁	Sigma/5-HT _{1A}
6	2	4	100	20,000	1,000	20	1000	0.5
7	3	10	400	10,000	30	6000	NT ^a	0.30
8	5	4	400	2000	> 100	3	100	1.25
9	5	30	700	2000	100	9	200	0.17
10	3	30	3000	20,000	> 10,000	7	500	0.10
11	2	40	900	8000	10,000	< 100	10,000	0.05
12	8	100	1000	20,000	100	10	NT ^a	0.08
13	9	200	900	2000	100	< 100	< 10,000	0.04
14	5	30	5000	3000	200	40	1,000	0.17
15	2	300	10,000	30,000	100	9	500	0.006
16	2000	> 10,000	> 10,000	> 10,000	> 10,000	20,000	> 10,000	0.20
17	100	> 100,000	> 100,000	> 100,000	> 100,000	> 100,000	> 100,000	0.001

^aNT not determined.

superior to 4-benzyl irrespective of the length (*n*) of the methylene linker between the benzothiazolinone and piperidine moiety while for 5-HT_{1A} affinity 4-phenyl and 4-benzyl substitution gave nearly equal scores, with however a superiority for *n* = 2.

Within the piperazine series, binding studies indicated that for sigma affinity 4-benzyl and 3,4-dichlorobenzyl substitutions were superior to 2,4-dichlorobenzyl with low incidence of the methylene number *n*; for 5-HT_{1A} affinity, scores ranked benzyl > 3,4-dichlorobenzyl > 2,4-dichlorobenzyl with *n* = 2 > *n* = 4. Conclusively, the best mixed σ/5-HT_{1A} affinity profile was found within the piperidine series with 4-benzyl substitution associated to *n* = 2 (*K_i* 5 and 4 nM, respectively). In addition, this study also shows that some of these compounds bind at H₁ receptor with nanomolar affinity (e.g., compounds **8**, **9**, **10** and **15** with *K_i* values of 3, 9, 7 and 9, respectively). Furthermore, **8** was found to be the best mixed σ/5-HT_{1A}/H₁ ligand while **9** and **10** exhibited a mixed σ/5-HT_{1A}/H₁ affinity profile less pronounced. Incidentally, a selective sigma (σ₂ vs σ₁) ligand (**15**) was obtained with 3,4-dichlorobenzyl associated to *n* = 4 (*K_i* 2 nM). This compound was also found to be a potent H₁ receptor ligand (*K_i* = 9 nM), thus suggesting that **15** has an interesting profile for both sigma and H₁ receptors. For compounds having high affinity for sigma sites, the selectivity ratio σ₁/σ₂ was measured. Sigma-1 affinity was measured using (+)-pentazocine as previously reported.³⁰ Sigma-2 affinity was measured using DTG as reported by Mach et al.³¹ The results indicate that compound **15** has much higher affinity at σ₂ than at σ₁ receptors (selectivity ratio = 70).

This situation is reminiscent of CB64D, CB184 and ibogaine, which are σ₂-selective ligands reported by Bowen et al.²³ Compound **15**, however has much higher σ₂ affinity when compared to these σ₂ ligands.

Further work is now being done to delineate the structure–activity relationship of selective sigma-2 ligands using compound **15** as lead structure.

Experimental

Chemistry

The synthesis strategy to afford the desired 6-aminoalkyl-2(3*H*)-benzothiazolones (**6–17**) was based on the initial elaboration of 6-bromoalkyl side chain on 3-methyl-(3*H*)-benzothiazolone. Two different approaches (route A and B) were established depending upon the number of methylene units (*n* = 2 or 4) as previously described.²⁹ Access to **2** and **5** was made possible by selective reduction of the ketone group (80–90% yield) using the couple triethylsilane-trifluoroacetic acid (Et₃SiH-TFA) according to the procedure described above.²⁹ Final products were obtained by treatment of compounds **2** or **5** by an appropriate heterocyclic amine (Scheme 1).

Pharmacology

Final compounds **6–17** were assessed for in vitro affinity at σ sites and 5-HT_{1A}, 5-HT_{2A}, M₁, H₁ and D₂ receptors (Table 2). The σ radioligand binding assays were carried out using [³H] (+)-pentazocine for σ₁ subtype receptors³⁰ and [³H] DTG in the presence of 1 μM (+)-pentazocine for σ₂ receptors (Table 3).³¹

The other receptor binding assays were done by ADIR & Cie (1, rue Carle Hébert, 92415 Corbevoie, France) and were performed using the following radioligands on rat brain membranes: [³H]prazosin (cortex), [³H]-8-OH-DPAT (hippocampus), [³H] ketanserin (cortex) for 5-HT_{1A}, 5HT_{2A} and 5-HT₃ receptors, respectively,

Table 3. σ₁/σ₂ selectivity ratio for compounds **6**, **11** and **15**. Binding measurements were done in triplicate

Compd	<i>K_i</i> (nM)		<i>n_H</i>	σ ₁ /σ ₂
	σ ₁	σ ₂		
6	20.0	2	1.05	10
11	37.2	2	0.94	19
15	139	2	0.74	70

[³H]pyrilamine for H₁ receptor, [³H]telenzepine for M₁, and [³H]raclopride (striatum) for D₂-dopamine receptors.

Acknowledgements

We thank ADIR et Cie Company (92415 Courbevoie, France) for financial support during this study and for collecting some of binding data.

References and Notes

1. Raymond, J. R.; Mukhin, Y. V.; Gettys, T. W.; Garnovskaya, M. N. *Br. J. Pharmacol.* **1999**, *127*, 1751.
2. Barros, M.; Mello, E. L.; Huston, J. P.; Tomaz, C. *Pharmacol. Biochem. Behav.* **2001**, *68*, 255.
3. Van Vliet, I. M.; Westenberg, H. G.; Den Boer, J. A. *Psychopharmacology* **1996**, *127*, 174.
4. File, S. E.; Gonzalez, L. E.; Andrews, N. *J. Neurosci.* **1996**, *16*, 4810.
5. Cassaday, H. J.; Simpson, E. L.; Gaffan, E. A. Q. *J. Exp. Psychol.* **2000**, *53B*, 225.
6. Harder, J. A.; Ridley, M. C. *Neuropharmacology* **2000**, *39*, 547.
7. Boast, C.; Bartolomeo, A. C.; Morris, H.; Moyer, J. *Neurobiol. Learn. Mem.* **1999**, *71*, 259.
8. Carli, M.; Silva, S.; Balducci, C.; Samanin, R. *Neuropharmacology* **1999**, *38*, 1165.
9. Bowen, W. D. *Pharm. Acta Helv.* **2000**, *74*, 211.
10. Schwarz, S.; Pohl, P.; Zhou, G. Z. *Science* **1989**, *246*, 1635.
11. Ault, D. T.; Werling, L. L. *Brain Res.* **2000**, *877*, 354.
12. Hornfeldt, C. S.; Kitto, K. F.; Larson, A. A. *Eur. J. Pharmacol.* **1996**, *306*, 15.
13. Hornfeldt, C. S.; Sun, X.; Larson, A. A. *J. Neurosci.* **1994**, *14*, 3364.
14. Quirion, R.; Bowen, W. D.; Itzhak, Y.; Junien, J. L.; Musacchio, J. M.; Rothman, R. B.; Su, T. P.; Tam, S. W.; Taylor, D. P. *Trends Pharmacol. Sci.* **1992**, *13*, 85.
15. Hanner, M.; Moebius, F. F.; Flandorfer, A.; Knaus, H. G.; Striessnig, J.; Kempner, E.; Glossmann, H. *Proc. Natl. Acad. Sci. U.S.A.* **1996**, *93*, 8072.
16. Esteban, A.; Traba, A.; Grandas, F. *Electroencephalogr. Clin. Neurophysiol.* **1997**, *103*, 90.
17. John, C. S.; Vilner, B. J.; Geyer, B. C.; Moody, T.; Bowen, W. D. *Cancer Res.* **1999**, *59*, 4578.
18. Ujie, H.; Kuroda, S.; Otsuki, S. *Eur. J. Pharmacol.* **1996**, *296*, 123.
19. Nakazawa, M.; Matsuno, K.; Mita, S. *Neurochem. Int.* **1998**, *32*, 337.
20. Ablordeppey, S. Y.; Fischer, J. B.; Glennon, R. A. *Bioorg. Med. Chem.* **2000**, *8*, 2105.
21. Glennon, R. A.; Ablordeppey, S. Y.; Ismaiel, A. M.; El-Ashmawy, M. B.; Fischer, J. B.; Howie, K. B. *J. Med. Chem.* **1994**, *37*, 1214.
22. Carroll, F. I.; Bai, X.; Zhang, X.; Brine, G. A.; Mascarella, S. W.; Di Paolo, L.; Wallace, P.; Walker, J. M.; Bowen, W. D. *Med. Chem. Res.* **1992**, *2*, 3.
23. Bowen, W. D.; Bertha, C. M.; Vilner, B. J.; Rice, K. C. *Eur. J. Pharmacol.* **1995**, *278*, 257.
24. Glennon, R. A.; Yousif, M. Y.; Ismaiel, A. M.; El-Ashmawy, M. B.; Herndon, J. L.; Fischer, J. B.; Server, A. C.; Howie, K. J. *J. Med. Chem.* **1991**, *34*, 3360.
25. Bantick, R. A.; Deakin, J. F.; Grasby, P. M. *J. Psychopharmacol.* **2001**, *15*, 37.
26. Mackowiak, M.; Czyrak, A.; Wedzony, K. *Psychiatr. Pol.* **2000**, *34*, 607.
27. Rollema, H.; Lu, Y.; Schmidt, A. W.; Zorn, S. H. *Eur. J. Pharmacol.* **1997**, *338*, R3.
28. Perrone, R.; Berardi, F.; Colabufo, N. A.; Leopoldo, M.; Abate, C.; Tortorella, V. *Med. Chem. Res.* **2000**, *10*, 201.
29. Taverne, T.; Diouf, O.; Depreux, P.; Poupaert, J. H.; Lesieur, D.; Guardiola-Lemaitre, B.; Renard, P.; Rettori, M. C.; Caignard, D. H.; Pfeiffer, B. *J. Med. Chem.* **1998**, *41*, 2010.
30. Ucar, H.; Cacciaguerra, S.; Spampinato, S.; Van derpoorten, K.; Isa, M.; Kanyonyo, M.; Poupaert, J. H. *Eur. J. Pharmacol.* **1997**, *335*, 267.
31. Mach, R. H.; Wu, L.; West, T.; Whirrett, B. R.; Childers, S. R. *Life Sci.* **1999**, *64*, 131.